Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon

Molecular Cell

Volumn 61, Issue 6, 2016, Pages 809-820

  Nguyen, T Van ^a   Lee, J Eugene ^a,b   Sweredoski, Michael J ^c   Yang, Seung Joo ^d   Jeon, Seung Je ^d   Harrison, Joseph S ^e   Yim, Jung Hyuk ^b   Lee, Sang Ghil ^b,f   Handa, Hiroshi ^g   Kuhlman, Brian ^e   Jeong, Ji Seon ^b   Reitsma, Justin M ^a   Park, Chul Seung ^d   Hess, Sonja ^c   Deshaies, Raymond J ^a,h  

^a California Institute of Technology   (United States)

^b Korea Research Institute of Standards and Science   (South Korea)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^d Gwangju Institute of Science and Technology (GIST)   (South Korea)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f Yonsei University   (South Korea)

^g TOKYO MEDICAL UNIVERSITY   (Japan)

^h HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBLON; CULLIN RING UBIQUITIN LIGASE 4; GLUTAMATE AMMONIA LIGASE; GLUTAMINE; LYSINE; PROTEASOME; RECEPTOR PROTEIN; THALIDOMIDE; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; CRBN PROTEIN, HUMAN; CRL4 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; PEPTIDE HYDROLASE;

ACETYLATION; AMINO TERMINAL SEQUENCE; ARTICLE; ENZYME DEGRADATION; FEEDBACK SYSTEM; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; UBIQUITINATION; HEK293 CELL LINE; HUMAN; METABOLISM; PROTEIN DEGRADATION;

ACETYLATION; GLUTAMATE-AMMONIA LIGASE; GLUTAMINE; HEK293 CELLS; HUMANS; IMMUNOLOGIC FACTORS; LYSINE; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; THALIDOMIDE; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84962499596     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2016.02.032     Document Type: Article

References (58)

1. Angers S., Li T., Yi X., MacCoss M.J., Moon R.T., Zheng N. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 2006, 443:590-593.
2. Arad G., Freikopf A., Kulka R.G. Glutamine-stimulated modification and degradation of glutamine synthetase in hepatoma tissue culture cells. Cell 1976, 8:95-101.
3. Araki T., Nagarajan R., Milbrandt J. Identification of genes induced in peripheral nerve after injury. Expression profiling and novel gene discovery. J. Biol. Chem. 2001, 276:34131-34141.
4. Bott A.J., Peng I.C., Fan Y., Faubert B., Zhao L., Li J., Neidler S., Sun Y., Jaber N., Krokowski D., et al. Oncogenic Myc induces expression of glutamine synthetase through promoter demethylation. Cell Metab. 2015, 22:1068-1077.
5. Bowers E.M., Yan G., Mukherjee C., Orry A., Wang L., Holbert M.A., Crump N.T., Hazzalin C.A., Liszczak G., Yuan H., et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 2010, 17:471-482.
6. Chamberlain P.P., Lopez-Girona A., Miller K., Carmel G., Pagarigan B., Chie-Leon B., Rychak E., Corral L.G., Ren Y.J., Wang M., et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 2014, 21:803-809.
7. Chen Y., Zhao W., Yang J.S., Cheng Z., Luo H., Lu Z., Tan M., Gu W., Zhao Y. Quantitative acetylome analysis reveals the roles of SIRT1 in regulating diverse substrates and cellular pathways. Mol. Cell. Proteomics 2012, 11:1048-1062.
8. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
9. Choudhary C., Weinert B.T., Nishida Y., Verdin E., Mann M. The growing landscape of lysine acetylation links metabolism and cell signalling. Nat. Rev. Mol. Cell Biol. 2014, 15:536-550.
10. Christa L., Simon M.T., Flinois J.P., Gebhardt R., Brechot C., Lasserre C. Overexpression of glutamine synthetase in human primary liver cancer. Gastroenterology 1994, 106:1312-1320.
11. Crook R.B., Tomkins G.M. Effect of glutamine on the degradation of glutamine synthetase in hepatoma tissue-culture cells. Biochem. J. 1978, 176:47-52.
12. Demars R. The inhibition by glutamine of glutamyl transferase formation in cultures of human cells. Biochim. Biophys. Acta 1958, 27:435-436.
13. Dhalluin C., Carlson J.E., Zeng L., He C., Aggarwal A.K., Zhou M.M. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999, 399:491-496.
14. Duan S., Cermak L., Pagan J.K., Rossi M., Martinengo C., di Celle P.F., Chapuy B., Shipp M., Chiarle R., Pagano M. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 2012, 481:90-93.
15. Fischer E.S., Böhm K., Lydeard J.R., Yang H., Stadler M.B., Cavadini S., Nagel J., Serluca F., Acker V., Lingaraju G.M., et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 2014, 512:49-53.
16. Grönroos E., Hellman U., Heldin C.H., Ericsson J. Control of Smad7 stability by competition between acetylation and ubiquitination. Mol. Cell 2002, 10:483-493.
17. Gunnersen D., Haley B. Detection of glutamine synthetase in the cerebrospinal fluid of Alzheimer diseased patients: a potential diagnostic biochemical marker. Proc. Natl. Acad. Sci. USA 1992, 89:11949-11953.
18. Häberle J., Görg B., Rutsch F., Schmidt E., Toutain A., Benoist J.F., Gelot A., Suc A.L., Höhne W., Schliess F., et al. Congenital glutamine deficiency with glutamine synthetase mutations. N. Engl. J. Med. 2005, 353:1926-1933.
19. Hensley C.T., Wasti A.T., DeBerardinis R.J. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J. Clin. Invest. 2013, 123:3678-3684.
20. Higgins J.J., Pucilowska J., Lombardi R.Q., Rooney J.P. A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 2004, 63:1927-1931.
21. Hohberger B., Enz R. Cereblon is expressed in the retina and binds to voltage-gated chloride channels. FEBS Lett. 2009, 583:633-637.
22. Ito A., Kawaguchi Y., Lai C.H., Kovacs J.J., Higashimoto Y., Appella E., Yao T.P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 2002, 21:6236-6245.
23. Ito T., Ando H., Suzuki T., Ogura T., Hotta K., Imamura Y., Yamaguchi Y., Handa H. Identification of a primary target of thalidomide teratogenicity. Science 2010, 327:1345-1350.
24. Jiang W., Wang S., Xiao M., Lin Y., Zhou L., Lei Q., Xiong Y., Guan K.L., Zhao S. Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol. Cell 2011, 43:33-44.
25. Jo S., Lee K.H., Song S., Jung Y.K., Park C.S. Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain. J. Neurochem. 2005, 94:1212-1224.
26. Kleiger G., Saha A., Lewis S., Kuhlman B., Deshaies R.J. Rapid E2-E3 assembly and disassembly enable processive ubiquitylation of cullin-RING ubiquitin ligase substrates. Cell 2009, 139:957-968.
27. Krajewski W.W., Collins R., Holmberg-Schiavone L., Jones T.A., Karlberg T., Mowbray S.L. Crystal structures of mammalian glutamine synthetases illustrate substrate-induced conformational changes and provide opportunities for drug and herbicide design. J. Mol. Biol. 2008, 375:217-228.
28. Krönke J., Udeshi N.D., Narla A., Grauman P., Hurst S.N., McConkey M., Svinkina T., Heckl D., Comer E., Li X., et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014, 343:301-305.
29. Krönke J., Fink E.C., Hollenbach P.W., MacBeth K.J., Hurst S.N., Udeshi N.D., Chamberlain P.P., Mani D.R., Man H.W., Gandhi A.K., et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature 2015, 523:183-188.
30. Kung H.N., Marks J.R., Chi J.T. Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet. 2011, 7:e1002229.
31. Lee J.E., Sweredoski M.J., Graham R.L., Kolawa N.J., Smith G.T., Hess S., Deshaies R.J. The steady-state repertoire of human SCF ubiquitin ligase complexes does not require ongoing Nedd8 conjugation. Mol. Cell. Proteomics 2011, 10. M110.006460.
32. Lee K.M., Jo S., Kim H., Lee J., Park C.S. Functional modulation of AMP-activated protein kinase by cereblon. Biochim. Biophys. Acta 2011, 1813:448-455.
33. Lee K.M., Yang S.J., Kim Y.D., Choi Y.D., Nam J.H., Choi C.S., Choi H.S., Park C.S. Disruption of the cereblon gene enhances hepatic AMPK activity and prevents high-fat diet-induced obesity and insulin resistance in mice. Diabetes 2013, 62:1855-1864.
34. Lee K.M., Yang S.J., Choi J.H., Park C.S. Functional effects of a pathogenic mutation in Cereblon (CRBN) on the regulation of protein synthesis via the AMPK-mTOR cascade. J. Biol. Chem. 2014, 289:23343-23352.
35. Lenz W., Pfeiffer R.A., Kosenow W., Hayman D.J. Thalidomide and congenital abnormalities. Lancet 1962, 279:45-46.
36. Lopez-Girona A., Mendy D., Ito T., Miller K., Gandhi A.K., Kang J., Karasawa S., Carmel G., Jackson P., Abbasian M., et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012, 26:2326-2335.
37. Lu G., Middleton R.E., Sun H., Naniong M., Ott C.J., Mitsiades C.S., Wong K.K., Bradner J.E., Kaelin W.G. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014, 343:305-309.
38. Lundby A., Lage K., Weinert B.T., Bekker-Jensen D.B., Secher A., Skovgaard T., Kelstrup C.D., Dmytriyev A., Choudhary C., Lundby C., Olsen J.V. Proteomic analysis of lysine acetylation sites in rat tissues reveals organ specificity and subcellular patterns. Cell Rep. 2012, 2:419-431.
39. Lv L., Li D., Zhao D., Lin R., Chu Y., Zhang H., Zha Z., Liu Y., Li Z., Xu Y., et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol. Cell 2011, 42:719-730.
40. Mcbride W.G. Thalidomide and congenital abnormalities. Lancet 1961, 278:1358.
41. Mujtaba S., Zeng L., Zhou M.M. Structure and acetyl-lysine recognition of the bromodomain. Oncogene 2007, 26:5521-5527.
42. Nicklin P., Bergman P., Zhang B., Triantafellow E., Wang H., Nyfeler B., Yang H., Hild M., Kung C., Wilson C., et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009, 136:521-534.
43. Paul J., Fottrell P.F. Mechanism of D-glutamyltransferase repression in mammalian cells. Biochim. Biophys. Acta 1963, 67:334-336.
44. Saitoh F., Araki T. Proteasomal degradation of glutamine synthetase regulates schwann cell differentiation. J. Neurosci. 2010, 30:1204-1212.
45. Soucy T.A., Smith P.G., Milhollen M.A., Berger A.J., Gavin J.M., Adhikari S., Brownell J.E., Burke K.E., Cardin D.P., Critchley S., et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009, 458:732-736.
46. Stadtman E.R. The story of glutamine synthetase regulation. J. Biol. Chem. 2001, 276:44357-44364.
47. Svinkina T., Gu H., Silva J.C., Mertins P., Qiao J., Fereshetian S., Jaffe J.D., Kuhn E., Udeshi N.D., Carr S.A. Deep, quantitative coverage of the lysine acetylome using novel anti-acetyl-lysine antibodies and an optimized proteomic workflow. Mol. Cell. Proteomics 2015, 14:2429-2440.
48. Tardito S., Oudin A., Ahmed S.U., Fack F., Keunen O., Zheng L., Miletic H., Sakariassen P.O., Weinstock A., Wagner A., et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat. Cell Biol. 2015, 17:1556-1568.
49. Taverna S.D., Li H., Ruthenburg A.J., Allis C.D., Patel D.J. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat. Struct. Mol. Biol. 2007, 14:1025-1040.
50. *. Biochem. Mol. Biol. Educ. 2004, 32:291-304.
51. Thompson P.R., Kurooka H., Nakatani Y., Cole P.A. Transcriptional coactivator protein p300. Kinetic characterization of its histone acetyltransferase activity. J. Biol. Chem. 2001, 276:33721-33729.
52. Van Nguyen T., Angkasekwinai P., Dou H., Lin F.-M., Lu L.-S., Cheng J., Chin Y.E., Dong C., Yeh E.T. SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol. Cell 2012, 45:210-221.
53. Wang Q., Zhang Y., Yang C., Xiong H., Lin Y., Yao J., Li H., Xie L., Zhao W., Yao Y., et al. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science 2010, 327:1004-1007.
54. Weinert B.T., Schölz C., Wagner S.A., Iesmantavicius V., Su D., Daniel J.A., Choudhary C. Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep. 2013, 4:842-851.
55. Wysocka J., Swigut T., Milne T.A., Dou Y., Zhang X., Burlingame A.L., Roeder R.G., Brivanlou A.H., Allis C.D. WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell 2005, 121:859-872.
56. Wysocka J., Swigut T., Xiao H., Milne T.A., Kwon S.Y., Landry J., Kauer M., Tackett A.J., Chait B.T., Badenhorst P., et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 2006, 442:86-90.
57. Zhao S., Xu W., Jiang W., Yu W., Lin Y., Zhang T., Yao J., Zhou L., Zeng Y., Li H., et al. Regulation of cellular metabolism by protein lysine acetylation. Science 2010, 327:1000-1004.
58. Zhu Y.X., Braggio E., Shi C.X., Bruins L.A., Schmidt J.E., Van Wier S., Chang X.B., Bjorklund C.C., Fonseca R., Bergsagel P.L., et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011, 118:4771-4779.